BACKGROUND. The antithrombotic efficacy of aspirin is attributed to its inhibition of the enzyme prostaglandin G/H synthase, which is necessary for the formation of thromboxane A2 in platelets. Thromboxane A2 is a potent vasoconstrictor and platelet agonist. However, the formation of prostacyclin by vascular endothelium also requires prostaglandin G/H synthase, and prostacyclin exerts opposite effects on platelet function and vascular tone. We wanted to see whether controlled-release aspirin would affect the formation of thromboxane A2 but not prostacyclin by reducing the aspirin concentration that reaches the posthepatic circulation. METHODS. A controlled-release formulation containing 75 mg of aspirin, designed to release 10 mg per hour, was developed to inhibit prostaglandin G/H synthase in platelets in the prehepatic circulation. The effects of the controlled-release preparation on plasma levels of aspirin and salicylate, serum levels of thromboxane B2, and urinary dinor metabolites of prostacyclin and thromboxane B2 (measured by gas chromatography-mass spectrometry) were compared with those of conventional immediate-release aspirin in normal volunteers. Prostacyclin release was stimulated by intravenous bradykinin. RESULTS. Steady-state inhibition of serum thromboxane B2 required two to four days and appeared slower with 75 mg of controlled-release than with the same amount of immediate-release aspirin. Maximal inhibition was achieved rapidly by adding a single loading dose of 162.5 mg of immediate-release aspirin to the regimen. Over a 28-day period, suppression of thromboxane A2 with this regimen was comparable to that with immediate-release aspirin taken either as 162.5 mg daily or as 325 mg on alternate days, despite the minimal systemic bioavailability of controlled-release aspirin. Bleeding time was prolonged to a similar degree with each of the three regimens. The five- to sixfold increase in the prostacyclin metabolite induced by bradykinin was depressed by pretreatment for four days with 75 mg of immediate-release aspirin, but not by 75 mg of controlled-release aspirin. CONCLUSIONS. Maximal inhibition of platelet thromboxane A2 production was sustained during long-term dosing with controlled-release aspirin, whereas basal prostacyclin biosynthesis fell only slightly and systemic synthesis of prostacyclin stimulated by bradykinin was preserved. Controlled-release aspirin may facilitate determination of the clinical importance of preserving prostacyclin during platelet inhibition in humans.
Source Information
Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.
This article has been cited by other articles:
Patrono, C., Baigent, C., Hirsh, J., Roth, G.
(2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 199S-233S
[Abstract][Full Text]
FitzGerald, G. A.
(2008). Summary. Arterioscler. Thromb. Vasc. Bio.
28: s51-s52
[Full Text]
Berger, J. S., Stebbins, A., Granger, C. B., Ohman, E. M., Armstrong, P. W., Van de Werf, F., White, H. D., Simes, R. J., Harrington, R. A., Califf, R. M., Peterson, E. D.
(2008). Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. Circulation
117: 192-199
[Abstract][Full Text]
Maree, A. O., Fitzgerald, D. J.
(2007). Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation
115: 2196-2207
[Full Text]
Cyrus, T., Yao, Y., Ding, T., Dogne, J. M., Pratico, D.
(2007). Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood
109: 3291-3296
[Abstract][Full Text]
Khasawneh, F. T., Huang, J.-S., Turek, J. W., Breton, G. C. L.
(2006). Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein. J. Biol. Chem.
281: 26951-26965
[Abstract][Full Text]
Robbins, I. M., Kawut, S. M., Yung, D., Reilly, M. P., Lloyd, W., Cunningham, G., Loscalzo, J., Kimmel, S. E., Christman, B. W., Barst, R. J.
(2006). A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension.. Eur Respir J
27: 578-584
[Abstract][Full Text]
Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., Baigent, C.
(2005). Low-dose aspirin for the prevention of atherothrombosis.. NEJM
353: 2373-2383
[Full Text]
Hermida, R. C., Ayala, D. E., Calvo, C., Lopez, J. E., Mojon, A., Rodriguez, M., Fernandez, J. R.
(2005). Differing Administration Time-Dependent Effects of Aspirin on Blood Pressure in Dipper and Non-Dipper Hypertensives. Hypertension
46: 1060-1068
[Abstract][Full Text]
Hermida, R. C., Ayala, D. E., Calvo, C., Lopez, J. E.
(2005). Aspirin Administered at Bedtime, But Not on Awakening, Has an Effect on Ambulatory Blood Pressure in Hypertensive Patients. J Am Coll Cardiol
46: 975-983
[Abstract][Full Text]
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G.
(2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 234S-264S
[Abstract][Full Text]
Fiorucci, S., Mencarelli, A., Meneguzzi, A., Lechi, A., Renga, B., del Soldato, P., Morelli, A., Minuz, P.
(2004). Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol
44: 635-641
[Abstract][Full Text]
Kearney, D., Byrne, A., Crean, P., Cox, D., Fitzgerald, D. J.
(2004). Optimal suppression of thromboxane a2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol
43: 526-531
[Abstract][Full Text]
Belton, O. A., Duffy, A., Toomey, S., Fitzgerald, D. J.
(2003). Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis. Circulation
108: 3017-3023
[Abstract][Full Text]
Hermida, R. C., Ayala, D. E., Calvo, C., Lopez, J. E., Fernandez, J. R., Mojon, A., Dominguez, M. J., Covelo, M.
(2003). Administration Time-Dependent Effects of Aspirin on Blood Pressure in Untreated Hypertensive Patients. Hypertension
41: 1259-1267
[Abstract][Full Text]
Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., Michel, B., Luscher, T. F., Noll, G., Ruschitzka, F.
(2003). Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease. Circulation
107: 405-409
[Abstract][Full Text]
Cyrus, T., Sung, S., Zhao, L., Funk, C. D., Tang, S., Pratico, D.
(2002). Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Circulation
106: 1282-1287
[Abstract][Full Text]
Turek, J. W., Halmos, T., Sullivan, N. L., Antonakis, K., Le Breton, G. C.
(2002). Mapping of a Ligand-binding Site for the Human Thromboxane A2 Receptor Protein. J. Biol. Chem.
277: 16791-16797
[Abstract][Full Text]
Connolly, E., Bouchier-Hayes, D. J., Kaye, E., Leahy, A., Fitzgerald, D., Belton, O.
(2002). Cyclooxygenase Isozyme Expression and Intimal Hyperplasia in a Rat Model of Balloon Angioplasty. J. Pharmacol. Exp. Ther.
300: 393-398
[Abstract][Full Text]
Yamada, M., Numaguchi, Y., Okumura, K., Harada, M., Naruse, K., Matsui, H., Ito, T., Hayakawa, T.
(2002). Prostacyclin Synthase Gene Transfer Modulates Cyclooxygenase-2-Derived Prostanoid Synthesis and Inhibits Neointimal Formation in Rat Balloon-Injured Arteries. Arterioscler. Thromb. Vasc. Bio.
22: 256-262
[Abstract][Full Text]
Robbins, I. M., Barst, R. J., Rubin, L. J., Gaine, S. P., Price, P. V., Morrow, J. D., Christman, B. W.
(2001). Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension. Chest
120: 1639-1644
[Abstract][Full Text]
Hurlen, M., Hole, T., Seljeflot, I., Arnesen, H.
(2001). Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. Eur J Heart Fail
3: 203-207
[Abstract][Full Text]
Herren, K R, Mackway-Jones, K
(2001). Emergency management of cardiac chest pain: a review. Emerg. Med. J.
18: 6-10
[Full Text]
Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G.
(2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest
119
: 39S-63S
[Full Text]
Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W.
(2001). Antithrombotic Agents in Coronary Artery Disease. Chest
119
: 228S-252S
[Full Text]
Belton, O., Byrne, D., Kearney, D., Leahy, A., Fitzgerald, D. J.
(2000). Cyclooxygenase-1 and -2-Dependent Prostacyclin Formation in Patients With Atherosclerosis. Circulation
102: 840-845
[Abstract][Full Text]
Awtry, E. H., Loscalzo, J.
(2000). Aspirin. Circulation
101: 1206-1218
[Full Text]
Oberle, S., Polte, T., Abate, A., Podhaisky, H.-P., Schroder, H.
(1998). Aspirin Increases Ferritin Synthesis in Endothelial Cells : A Novel Antioxidant Pathway. Circ. Res.
82: 1016-1020
[Abstract][Full Text]
Altman, R.
(1998). Controversies in Antithrombotic Therapy in Cardiovascular Diseases. CLIN APPL THROMB HEMOST
4: 11-24
[Abstract]
Collins, R., Peto, R., Baigent, C., Sleight, P.
(1997). Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. NEJM
336: 847-860
[Full Text]
Alhaddad, I. A., Tkaczevski, L., Siddiqui, F., Mir, R., Brown, E. J. Jr
(1995). Aspirin Enhances the Benefits of Late Reperfusion on Infarct Shape : A Possible Mechanism of the Beneficial Effects of Aspirin on Survival After Acute Myocardial Infarction. Circulation
91: 2819-2823
[Abstract][Full Text]
Minar, E., Ahmadi, A., Koppensteiner, R., Maca, Th., Stumpflen, A., Ugurluoglu, A., Ehringer, H.
(1995). Comparison of Effects of High-Dose and Low-Dose Aspirin on Restenosis After Femoropopliteal Percutaneous Transluminal Angioplasty. Circulation
91: 2167-2173
[Abstract][Full Text]
Vial, J. H., Narkowicz, C.
(1995). Comparison of Cyclooxygenase Inhibition with Two Different Doses of Enteric Coated Aspirin in Normal Young and Elderly Subjects and Elderly with Cerebrovascular Disease. CLIN APPL THROMB HEMOST
1: 55-61
[Abstract]
Patrono, C.
(1994). Aspirin as an Antiplatelet Drug. NEJM
330: 1287-1294
[Full Text]
Cannegieter, S.C., van der Meer, F.J.M., Briet, E., Rosendaal, F.R., Bussey, H. I., Linn, W. D., Keimowitz, R. M., Fitzgerald, D. J., Turpie, A.G.G., Gent, M., Laupacis, A., Hirsh, J.
(1994). Warfarin and Aspirin after Heart-Valve Replacement. NEJM
330: 507-509
[Full Text]
Antiplatelet Trialists,
(1994). Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ
308: 81-106
[Abstract][Full Text]
Gentile, A. T., DeLoughery, T. G., Porter, J. M.
(1994). Novel Antithrombotic Agents in Vascular Surgery. PERSPECT VASC SURG ENDOVASC THER
7: 57-72
Turpie, A., Gent, M., Laupacis, A., Latour, Y., Gunstensen, J., Basile, F., Klimek, M., Hirsh, J.
(1993). A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement. NEJM
329: 524-529
[Abstract][Full Text]
Kearon, C., Hirsh, J.
(1993). Optimal Dose for Starting and Maintaining Low-Dose Aspirin. Arch Intern Med
153: 700-702
[Abstract]
Shebuski, R. J.
(1993). Interruption of Thrombosis and Hemostasis by Anti-Platelet Agents. Toxicol Pathol
21: 180-189
[Abstract]
Previous
